Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP

November 24, 2025

Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP

Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) announced today that the University of Bonn, Germany is now actively screening patients for the Phase 3 Serenta clinical trial evaluating eRapa in familial adenomatous polyposis (FAP). This marks the first European site activation for the registrational Serenta trial, representing a major milestone in expanding FAP treatment options to European patients who currently have no approved non-surgical therapeutic alternatives.

Read more at globenewswire.com